Reversal Reaction in A Borderline Lepromatous Leprosy Patient after COVID-19 Vaccine: Prevention or Risks?

Authors

  • Odelia Jovita Jusuf Fantoni Dermatology and Venereology Department, Sriwijaya University, Dr. Moh. General Hospital, Palembang, Indonesia

DOI:

https://doi.org/10.66344/jpad.32.3.2022.1953

Abstract

Reversal reaction in leprosy is an immunologically mediated response due to alteration of cell-mediated immunity associated in leprosy spectrum. In COVID-19 pandemic era, leprosy patient is susceptible to the infection. According to guideline, vaccination should be given to leprosy patients. This case reported a 33-year-old male with reversal reaction after COVID-19 vaccination. On examination, patient had erythematous plaque of the face, trunk and extremities, also multiple ulcers of the trunk and extremities. Treatment was commenced immediately with prednisone and second vaccination was delayed. Within our follow-up, marked improvement were obtained after 6 weeks.

Downloads

Published

2022-08-27

How to Cite

1.
Fantoni OJJ. Reversal Reaction in A Borderline Lepromatous Leprosy Patient after COVID-19 Vaccine: Prevention or Risks?. J Pak Assoc Dermatol [Internet]. 2022Aug.27 [cited 2026Apr.8];32(3):609-12. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1953

Issue

Vol. 32 No. 3 (2022): July - September

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.